Effect of rhBNP on CMD in Patients With STEMI After PPCI

STEMI Clinical Trial

Official title:

Effect of rhBNP on Coronary Microcirculation in Patients With Acute ST-segment Elevation Myocardial Infarction After Primary PCI

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05723315
• Other study ID #: HenanICE202301
• Status: Not yet recruiting
• Phase: N/A
• Start date: February 20, 2023
• Est. completion date: December 20, 2025

Study information

• Verified date: February 2023
• Source: Henan Institute of Cardiovascular Epidemiology
• Contact: Quan Guo
• Phone: +8615670510031
• Email: xinyiguoquan[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The target population of this interventional study was STEMI patients. Primary discussion: Early rhBNP reduces microcirculation obstruction in STEMI patients undergoing primary PCI

Description:

Direct percutaneous coronary intervention is the preferred reperfusion strategy for acute ST-segment elevation myocardial infarction. During the opening of infarct-related vessels, 5%-50% of patients showed slow flow or no reflow and other coronary microcirculation dysfunction, which aggravated myocardial injury and increased the incidence and mortality of heart failure. Studies have shown that recombinant human brain natriuretic peptide (rhBNP) can reduce reperfusion injury and reduce myocardial infarction area CMD. Prolonged ischemia leads to rapid depletion of intracellular ATP and tissue metabolic acidosis. Blood flow irrigation during reperfusion leads to decreased levels of ATP precursors, calcium overload in mitochondria, release of a large number of inflammatory factors and oxygen free radicals, which can lead to injury or death of myocardial and endothelial cells. rhBNP can enhance the activity of antioxidant enzymes, reduce the irreversible oxidative damage caused by free radicals to myocardium, reduce the myocardial infarction area during ischemia reperfusion, and may reduce the reperfusion injury and protect the viable myocardium.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 160
• Est. completion date: December 20, 2025
• Est. primary completion date: December 20, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• STEMI
• PPCI within 24 hours of symptom onset
• Target vessel QFR-MR>250mm Hg*s/m

Exclusion Criteria:

• claustrophobia
• Postoperative TIMI grade 0-1
• Pregnancy

Related Conditions & MeSH terms

• ST Elevation Myocardial Infarction
• STEMI

Intervention

Drug:
• recombinant human B-type natriuretic peptide
The recombinant human B-type natriuretic peptide produces physiological effects by imitating endogenous B-type natriuretic peptide

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Henan Institute of Cardiovascular Epidemiology

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MVO/LV(%)	Microvascular obstruction assessed by magnetic resonance imaging	3-14 days after PPCI
Secondary	LGE/LV(%)	Cardiac magnetic resonance imaging	3-14 days and 90±7 days after PPCI
Secondary	IMH	Intramuscular hemorrhageCardiac assessed by magnetic resonance imaging	3-14 days after PPCI
Secondary	MVO/LV(%)	Microvascular obstruction assessed by magnetic resonance imaging	30±7 days after PPCI
Secondary	LVEDV(ml)	Assessed by magnetic resonance imaging	3-14 days and 90±7 days after PPCI
Secondary	LVESV(ml)	Assessed by magnetic resonance imaging	3-14 days and 90±7 days after PPCI
Secondary	Troponin (highest value)	Troponin (highest value)	3-14 days after PPCI
Secondary	MACCEs	Major Adverse Cardiac and Cerebrovascular event:Death, nonfatal myocardial infarction, heart failure, revascularization, stroke	7days,30days,3months,6 months